New drug tracking study launches for rare genetic cancer
NCT ID NCT06672523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looks at how a new drug (BMS-986504) moves through and leaves the body in people with advanced solid tumors that have a specific missing gene (MTAP deletion). The main goal is to understand the drug's breakdown and elimination, not to treat the cancer directly. Only 8 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid,
RECRUITINGMadrid, 28050, Spain
Contact Phone: •••-•••-••••
-
ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely
RECRUITINGBudapest, 1076, Hungary
Contact Phone: •••-•••-••••
-
START Rioja, The START Center for cancer research
RECRUITINGLogroño, 26006, Spain
Contact Phone: •••-•••-••••